The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients

Nephron - Clinical Practice

Volumn 121, Issue 1-2, 2012, Pages

  Sinsakul, Marvin ^a   Sika, Mohammed ^c   Koury, Mark ^e   Shapiro, Warren ^b   Greene, Tom ^d   Dwyer, Jamie ^e   Smith, Mark ^d   Korbet, Stephen ^a   Lewis, Julia ^e  

^a Circle Medical Management ^*  (United States)

^b Brookdale Medical Center   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Kidney Care Associates   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Binder; Citrate; Dialysis; Ferric; Phosphorus

Indexed keywords

CALCIUM; CALCIUM ACETATE; FERRIC CITRATE; FERRITIN; IRON; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; TRANSFERRIN;

ABDOMINAL CRAMP; ADULT; ANOREXIA; ARTICLE; BICARBONATE BLOOD LEVEL; BLOATING; BLOOD CELL COUNT; BLOOD CHEMISTRY; CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES COLOR; FEMALE; HEARTBURN; HEMODIALYSIS PATIENT; HUMAN; INCREASED APPETITE; IRON ABSORPTION; IRON BLOOD LEVEL; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; STOMACH PAIN; STOMACH ULCER; TASTE DISORDER; VOMITING; XEROSTOMIA;

ADULT; CHELATING AGENTS; COLOR; CONSTIPATION; FECES; FEMALE; FERRIC COMPOUNDS; FERRITINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; QUESTIONNAIRES; RENAL DIALYSIS; RENAL OSTEODYSTROPHY;

EID: 84871668470     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000341922     Document Type: Article

References (10)

1. Hutchison A: Oral phosphate binders. Kidney Int 2009; 75: 906-914.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
3. Delmez J, Block G, Robertson J, et al: A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007; 68: 386-391. (Pubitemid 350258767)
4. St. Peter WL, Fan Q, Weinhandl E, Liu J: Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. Clin J Am Soc Nephrol 2009; 4: 1954-1961.
5. Koury MJ, Ponka P: New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr 2004; 24: 105-131. (Pubitemid 38938788)
6. Yang WC, Yang CS, Hou CC, Wu TH, Young E, Hsu CH: An open label, cross-over study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant 2002; 17: 265-270. (Pubitemid 34157141)
7. Emmett M: A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int 2004; 66:S25-S32. (Pubitemid 39121056)
8. Hsu CH, Patel SR, Young EW: New phosphate binding agents: ferric compounds. J Am Soc Nephrol 1999; 10: 1274-1280. (Pubitemid 29246992)
9. Van Wyck DB: Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management. Semin Nephrol 1989; 9(suppl 2):21-28.
10. The United States Renal Data System. USRDS 2010 Annual Data Report, Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States: Clinical Indicators and Preventive Health. Am J Kidney Dis 2011;57(suppl 1):e287-e300.